Affordable Access

deepdyve-link
Publisher Website

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors
  • Garassino, Marina Chiara1
  • Martelli, Olga
  • Broggini, Massimo
  • Farina, Gabriella
  • Veronese, Silvio
  • Rulli, Eliana
  • Bianchi, Filippo
  • Bettini, Anna
  • Longo, Flavia
  • Moscetti, Luca
  • Tomirotti, Maurizio
  • Marabese, Mirko
  • Ganzinelli, Monica
  • Lauricella, Calogero
  • Labianca, Roberto
  • Floriani, Irene
  • Giaccone, Giuseppe
  • Torri, Valter
  • Scanni, Alberto
  • Marsoni, Silvia
  • 1 Department of Medical Oncology, Fatebenefratelli e Oftalmico Hospital, Milan, [email protected] , (Italy)
Type
Published Article
Journal
The Lancet. Oncology
Publication Date
Sep 01, 2013
Volume
14
Issue
10
Pages
981–988
Identifiers
DOI: 10.1016/S1470-2045(13)70310-3
PMID: 23883922
Source
Medline
License
Unknown

Abstract

Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours.

Report this publication

Statistics

Seen <100 times